Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.51 +0.78 (+2.81%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge

February 13, 2026

The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades....

Via MarketMinute

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...

Via MarketMinute

Topics Bonds ETFs Economy

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

February 12, 2026

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Via Stocktwits

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗

February 03, 2026

Via Stocktwits

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

Via Stocktwits

Viking Therapeutics Stock Soars: What's Driving The Momentum? ↗

February 12, 2026

Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.

Via Benzinga

Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗

February 12, 2026

Via Stocktwits

Topics Stocks

Viking (VKTX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Viking (VKTX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours ↗

February 11, 2026

Via Stocktwits

Topics Government Stocks

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Via Stocktwits

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Via The Motley Fool

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

Could these two companies be biotech giants in the making?

Via The Motley Fool

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

Via The Motley Fool

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

February 07, 2026

The most recent gold rush in weight loss drugs isn't done just yet.

Via The Motley Fool

Topics Economy

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

Via MarketMinute

Topics Earnings Economy

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

The Smartest Growth Stock to Buy With $30 Right Now ↗

February 03, 2026

This pre-revenue biopharmaceutical stock is a home run swing worth taking.

Via The Motley Fool

2 Biotech Stocks Set to Rebound in 2026 ↗

January 27, 2026

They could perhaps see sustained runs beyond this year.

Via The Motley Fool

Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗

January 26, 2026

Both companies may succeed in this industry.

Via The Motley Fool

3 Growth Stocks to Invest $1,000 in Right Now ↗

January 24, 2026

It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.

Via The Motley Fool

Topics Artificial Intelligence

The Best Stocks to Invest $40 in to Start the New Year Off Right ↗

January 24, 2026

Both could reward patient investors down the line.

Via The Motley Fool

Topics Intellectual Property World Trade

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Via Finterra

Topics Intellectual Property

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗

January 23, 2026

This biotech has candidates in late-stage clinical development.

Via The Motley Fool

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

Via MarketMinute

Topics Economy

2 Bargain Stocks You Can Buy for Less Than $100 Right Now ↗

January 21, 2026

These stocks have struggled over the past year but may possess plenty of upside in the future.

Via The Motley Fool

1 Stock That Could Soar by 175%, According to Wall Street ↗

January 21, 2026

Can it become the next biotech leader?

Via The Motley Fool

What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗

January 20, 2026

Despite a challenging year, the company has a lot to look forward to in the coming years.

Via The Motley Fool

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗

January 20, 2026

Via MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

Via Finterra

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.